• Explore /
  • Poster
  • / Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.

Abstract Video & Slides Poster

Authors

Michael Atkins

Michael B. Atkins

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC

Michael B. Atkins , Igor Puzanov , Elizabeth R. Plimack , Mayer N. Fishman , David F. McDermott , Daniel C. Cho , Ulka N. Vaishampayan , Saby George , Jamal Christo Tarazi , William Duggan , Rodolfo F. Perini , Kathrine C. Fernandez , Toni K. Choueiri

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02133742

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5080)

DOI

10.1200/JCO.2020.38.15_suppl.5080

Abstract #

5080

Poster Bd #

149

Abstract Disclosures

Similar Posters

First Author: Bradley Alexander McGregor

Poster

2020 Genitourinary Cancers Symposium

Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.

Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.

First Author: Arielle G. Bensimon

First Author: Sun Young Rha

First Author: Viktor Grünwald